Intuitive Surgical Q2 2026 Earnings Analysis

Intuitive Surgical Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) [https://betafinch.com/groups/HEALTHCARE)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Intuitive Surgical's second quarter 2026 results. Before we get going, I do need to say — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And with that out of the way, Alex, this was actually a pretty strong quarter for Intuitive on paper. ALEX: It was. Revenue up 19% to $2.89 billion, non-GAAP EPS up 28% to $2.80 a share, operating margin at 42%. Total procedures grew 16%, with da Vinci procedures up 15% and Ion — their lung biopsy platform — up a huge 36%. JORDAN: There's a wrinkle in that gross margin number though. It came in at 70%, but $36 million of that was a one-time tariff refund benefit. Strip that out and you're looking at 68.7%, which is still solid, but worth noting when you're comparing quarters. ALEX: Right, and they actually raised full-year gross margin guidance because of that — now 68% to 69%, up from 67.5% to 68.5%. But here's the part that got analysts' attention: U.S. da Vinci procedure growth moderated to 12%, down from 14% in Q1. JORDAN: Yeah, and CFO Jamie Samath was pretty direct about why. They're seeing signs that patients are deferring elective procedures, and they specifically flagged the expiration of ACA enhanced premium subsidies as a factor. Basically, when people's insurance costs go up or coverage gets murkier, they push off surgeries that can wait. ALEX: The CEO, Dave Rosa, made a point of saying the underlying disease burden hasn't changed — people aren't getting healthier, they're just delaying care. Which, if you're an investor, is either reassuring or a "wait and see," depending on how you read it. JORDAN: There's also the GLP-1 story continuing to play out — bariatric procedures in the U.S. declined high-single-digits this quarter as more patients manage weight through drugs like Ozempic instead of surgery. ALEX: Let's talk strategy, because there was a lot packed into this call. The big one: the Extended Use Program. Starting in early 2027, Intuitive plans to increase the number of uses allowed on a subset of their EndoWrist instruments, specifically targeting lower-cost, high-volume benign procedures. JORDAN: This is a classic Intuitive move — they did something similar back in 2020. The idea is: lower the cost per procedure for hospitals, which drives more adoption, which drives more scale. An analyst on the call, Travis Steed, tried to get them to size the financial impact — he was fishing for whether this repeats the roughly 7-point hit to instrument revenue per procedure they saw last time. ALEX: And management wouldn't bite. Jamie Samath said flat out they're not ready to quantify it and will give more detail next quarter. So that's a real overhang to watch heading into 2027 guidance. JORDAN: The other big theme was geographic. China remains genuinely tough — increased domestic robotic competition, pricing pressure, and a new centralized tender process the government is rolling out. Dave Rosa was careful to say it's not quite the same as the volume-based pricing programs we've seen hit other device makers, but it's clearly something to watch. ALEX: Japan, on the other hand, looked more encouraging. New reimbursement policies kicked in June 1st, and they already saw system placements jump — 25 systems in Japan this quarter versus 15 a year ago. JORDAN: And then there's da Vinci 5, which is really the growth engine right now. They placed 468 total da Vinci systems, 246 of those were da Vinci 5, including 114 dual-console setups. The installed base is over 1,700 systems and 15,000 surgeons trained on it already. ALEX: One thing that stood out to me in t This episode includes AI-generated content.

Charles Schwab Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: BANKS (https://betafinch.com/groups/BANKS) [https://betafinch.com/groups/BANKS)] ────────── Welcome to Beta Finch, your AI-powered earnings breakdown of the numbers that matter, the stories behind them, and what it all means for you. ALEX: Hey everyone, welcome back to Beta Finch! I'm Alex, here with Jordan, and today we're digging into Charles Schwab's Q2 2026 results — and Jordan, this one's got a headline number that jumped off the page. JORDAN: It really did. ALEX: Before we get into it, quick reminder — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Right, so let's start with the topline. Schwab posted $7.1 billion in total revenue, up 21% year-over-year, and adjusted EPS of $1.62 — that's a 42% jump from last year. That's not incremental growth, that's a genuinely strong quarter. ALEX: And it wasn't just one line item carrying the load. Net interest revenue was up 19%, asset management fees up 16% to $1.8 billion, and trading revenue jumped 28% to $1.2 billion on 11.9 million daily average trades. That's a company firing on basically every cylinder. JORDAN: What stood out to me is where that net interest strength is coming from. It's not just sitting on deposits and collecting spread passively — bank lending balances hit $67 billion, up 33% year-over-year, largely driven by their Pledged Asset Line product. Clients are borrowing against their portfolios instead of selling appreciated stock, which is a pretty clever way to deepen the relationship without pushing clients out of their positions. ALEX: Yeah, CEO Rick Wurster made that point explicitly in the call — someone with a big embedded gain who wants access to cash, they don't want to sell and trigger taxes, so they pledge the assets instead. And apparently only about half a percent of Schwab clients use one of these lending products today, versus 4% industry-wide. So there's a long runway there. JORDAN: That "lending penetration gap" language really jumped out at me. If they can even partially close that gap, it's a meaningful, durable growth lever — not a one-quarter sugar high. ALEX: Let's talk client growth too, because the numbers there are big. 1.4 million new brokerage accounts in the quarter, $120 billion in core net new assets — up almost 50% year-over-year. And zooming out to the first half of the year, $2.7 million new accounts and $260 billion in net new assets. JORDAN: And management reiterated they expect 5% or higher organic growth as the long-term target across their three businesses — Investor Services, Advisor Services, and the workplace/retirement business. Advisor Services in particular has been running above that, 6%-plus the last four quarters, as independent RIAs keep gaining share. ALEX: There's also a strategic thread running through this call that I think is worth pulling on — Schwab really positioning itself as the "one-stop shop" for people's entire financial life. Wealth, banking, lending, trading, and now increasingly private markets and crypto. JORDAN: Right, they closed the Forge acquisition for private markets access, they're piloting crypto transfers by the end of the month, and they made an investment in Paxos to support that crypto rollout. None of that is moving the needle financially yet — CFO Mike Verdeschi was upfront that these are smaller contributors for now — but it rounds out the platform. ALEX: The wealth advice opportunity might actually be the bigger long-term story, though. Wurster pointed out the U.S. retail advice market is $37 trillion, and Schwab only has about 2% share. Only 5% of Schwab retail households are currently on a fee-based advice solution, even though 31% say they'd be willing to pay for advice. JORDAN: And clients on their Schwab Wealth Advisory offer generate t This episode includes AI-generated content.

3M Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: INCOME (https://betafinch.com/groups/INCOME) [https://betafinch.com/groups/INCOME)], INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS) [https://betafinch.com/groups/INDUSTRIALS)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into 3M's second quarter 2026 results, and there's a lot to unpack here. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And Alex, this was genuinely a strong quarter for 3M. Organic growth of 5.4%, operating margin at 24.9% — that's their highest ever, by the way — EPS of $2.40, up 11% year-over-year, and free cash flow of $1.3 billion with 107% conversion. That's about as clean a beat as you'll see. ALEX: Right, and they didn't just beat expectations, they raised guidance across the board. Full-year organic growth guidance moved from 3% to greater than 3.5%. EPS guidance went from $8.50-$8.70 up to $8.80-$8.95. Free cash flow guidance ticked up $100 million to $4.7-$4.9 billion. JORDAN: What stood out to me is CEO Bill Brown was pretty emphatic this isn't a macro tailwind story. CFO Anurag Maheshwari basically said the same thing on the call — this is internal execution. Commercial excellence initiatives, better sales force effectiveness, cross-selling that's running 40% ahead quarter-over-quarter, and customer attrition improving about 200 basis points, mostly in their Safety & Industrial business. ALEX: And the innovation piece is a big part of the story too. They launched 92 new products in the quarter, up 44% year-over-year, putting them on pace for more than 350 new products this year. They're targeting over 1,000 new product launches by 2027, and development cycle time is down about 20%. JORDAN: The segment breakdown really tells the story. Safety & Industrial — that's SIBG — grew 8.2%, with double-digit growth across electrical markets, adhesives and tapes, abrasives, and industrial specialties. Transportation and Electronics grew 5.9%, helped by strength in semiconductors, aerospace, and data centers. But Consumer was the soft spot, down 2.1% for the quarter because of some retailer destocking in late June. ALEX: Now let's talk about the headline strategic news, because this is the part that got analysts excited. 3M announced a partnership with Microsoft — they're the first hyperscaler to deploy 3M's Expanded Beam Optical technology, or EBO, in Azure data centers. JORDAN: This is fascinating from a materials science angle. EBO is basically a more durable, dust-resistant fiber optic connector that Brown said can cut installation time in data centers by about 85%. They've got 100 patents already, 50 more pending. Revenue this year is only in the $40-50 million range, but Brown said it could scale 4x or 5x — or more — over the next few years as the broader market shifts from copper to optical. ALEX: And they're not trying to own the whole ecosystem either. They formed a 44-player multi-supplier agreement across hyperscalers, chip makers, and connector manufacturers. Brown was clear — they won't succeed as a sole provider, this is about industry-wide adoption. JORDAN: There was also the Madison Fire & Rescue deal — they closed on July 1st, folding it into their Scott SCBA business as a majority-owned joint venture, and picked up $700 million in cash in the process. That JV does about $800 million in revenue, growing high single digits with above-average margins. Classic example of reshaping the portfolio toward higher-growth, higher-margin businesses. ALEX: One thing I want to flag from the Q&A — China came up, and it's a much better story than a lot of people expected. Double-digit growth in the quarter, about 8% for the first half, and that's the seventh straight quarter of double-digit growth in India specifica This episode includes AI-generated content.

Netflix Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: FAANG (https://betafinch.com/groups/FAANG) [https://betafinch.com/groups/FAANG)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Netflix's Q2 2026 numbers, and there's a lot to unpack here. Before we dive in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Alright Alex, let's start with the topline. Revenue growth is guided at 12% for Q3, 11% FX-neutral, which is a slight deceleration from Q2's 12%. Some analysts flagged that. ALEX: Right, but CFO Spencer Neumann pretty much waved that off. His point was they don't manage quarter to quarter — they manage to the full year. And the full year guide is 13-14% top-line growth, roughly $6 billion in incremental revenue. JORDAN: And the context he gave was pretty staggering. They're calling themselves "still just getting started" — under 45% penetrated into their addressable 800 million households, and only capturing about 7% of a $670 billion addressable revenue market. That's a big runway claim. ALEX: It is. Let's talk engagement, because this was clearly the hot topic on the call — multiple analysts pushed on viewing hours softening. Co-CEO Greg Peters gave this whole framework: quality, variety, quantity, and made the point that not all hours are created equal. JORDAN: The live programming example was the standout for me. Live is about 5% of their content budget but only 1% of view hours — yet six of the top ten sign-up days in the last five years came from live events. Compare that to animation and kids' content, same 5% of spend, but 8% of view hours. Totally different jobs for the content to do. ALEX: And the actual number — view hours grew 2% in the first half of 2026, a slight acceleration from 1.5% last year. So the "engagement is dying" narrative doesn't really hold up in the data they're showing. JORDAN: Ted Sarandos also pushed back hard on the Season 2 drop-off question — said their second-season fall-off is actually slightly improved year over year, no change in release strategy needed. ALEX: Let's get into content spend, because that's where the checkbook talk gets interesting. Content expense is up about 10% this year — higher than their five-year average of 8%, but still below the 14% decade average. So spend is accelerating a bit, but they're framing it as disciplined, growing slower than revenue. JORDAN: And the slate highlights were fun — "I Will Find You" was their biggest original series launch this year, "Swapped" is tracking to be their second-biggest animated film ever behind K-Pop: Demon Hunters. Plus some great international examples — a Zimbabwean novel adapted into a South African hit called "The Polygamist," and "Rosario Tijeras" in Latin America getting a Season 6 greenlight. ALEX: That global content engine is really Netflix's moat at this point. Now, let's talk monetization — ads and pricing. Greg Peters said they manage the ads business for total revenue growth, and there's still a gap between ad-tier ARM and the standard-without-ads tier ARM. He's framing that gap as "under-realized revenue" — basically future growth already baked into the roadmap as they close it. JORDAN: On pricing, first-half price increases in the U.S., Mexico, and Spain are going "consistent with expectations" — no surprises there. And Peters made a value argument too — saying Netflix subscribers pay the least per hour of viewing compared to other SVOD services, with the ad tier at $8.99 in the U.S. being what he called an incredible entry point. ALEX: Let's touch on some of the newer bets — gaming and AI. Cloud gaming had a strong quarter: FIFA and Unhinged were their two most successful cloud game debuts, and monthly active players for cloud games are up 11x since O This episode includes AI-generated content.

UnitedHealth Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) [https://betafinch.com/groups/HEALTHCARE)] ────────── **BETA FINCH — UnitedHealth Group (UNH) Q2 2026 Earnings Breakdown** ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into UnitedHealth Group's second quarter 2026 results — a quarter that, honestly, marks a pretty big turnaround story. JORDAN: Big turnaround is right. But before we get into it — quick reminder for everyone listening. ALEX: Right, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Good, now let's get into it. ALEX: So let's start with the headline numbers, because they're strong. Adjusted EPS came in at $6.38, up from $4.08 a year ago — that's a huge jump. Revenue was about $112 billion, roughly flat year-over-year, but operating earnings grew 55%. And they raised full-year guidance to a range of $19.50 to $20 a share. JORDAN: What jumps out to me is the medical care ratio — that's basically the percentage of premium revenue that goes out the door in medical claims. It dropped to 86.7% from 89.4% last year. Lower is better for the insurer. Part of that is $860 million in favorable prior-period development, meaning they overestimated costs in prior periods and get to release some of that reserve now. But even stripping that out, the underlying trend is improving. ALEX: And this is really the story CEO Stephen Hemsley told at the top of the call — this is a company about a year into a restructuring after a rough stretch, and he was pretty clear: "we will remain restless." He's not declaring victory, but the discipline is showing up in the numbers. JORDAN: Let's talk segments, because the picture is genuinely split. Medicare Advantage was the star of the quarter. Membership retention beat expectations, they now expect MA enrollment to decline by only about 1.1 million instead of more, and Medicare margins are tracking above 3% for the year. Medical trend also came in below their original 10% estimate — helped by benefit redesign, network curation, and honestly, a milder flu season. ALEX: Meanwhile, commercial is the soft spot. Cost trends are running modestly above 11%, worse than they'd hoped. Management pointed to two specific culprits: the No Surprises Act's arbitration process — which they say is being exploited, with average payouts to out-of-network providers now 11 times what Medicare would pay — and more aggressive provider billing and coding practices. JORDAN: That arbitration point was one of the more eye-opening moments in the Q&A. Executive Dan Kueter said roughly 60% of all arbitration cases are now brought by just five entities, and 40% of claims entering the process are actually ineligible to begin with. It's clogging the system and driving costs up. The upshot: commercial margin recovery, which they'd hoped to complete by 2027, is now going to take longer. Not derailed, in their words — just delayed. ALEX: Medicaid, meanwhile, is basically playing out as planned — margins pressured, expected to land between -1% and -1.7% for the year, as state reimbursement rates lag behind medical cost growth. Nothing new there, just a slow grind toward better alignment with states. JORDAN: Now let's flip to Optum, the services side of the business, because that's where a lot of the AI story lives. Optum Health — their value-based care arm — is showing real improvement: a roughly 10% reduction in hospitalizations in regions where they've rolled out new care transition programs, and patient satisfaction up about 5% year-over-year. ALEX: Optum Rx, the pharmacy benefit manager, is leaning hard into transparency — they're on track to have more than 95% of clients on 100% rebate pass-through by year-end. This episode includes AI-generated content.